Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

30 March 2022: Clinical Research

Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse

Liyang Zhou 1ABCDEF* , Qin He 1CEF* , Xitao Liu 2DEF* , Xiaoan Yang 3BC , Xueting Ou 1EF , Bing Situ 2DF , Yueping Li 4DE , Xingfei Pan 1DEFG* , Qihuan Xu 3AE*

DOI: 10.12659/MSM.934785

Med Sci Monit 2022; 28:e934785

Figure 3 (A) Difference in the cumulative rate of clinical suppression between A1 and group A2 (P<0.01). Group A1, the normal alanine aminotransferase (ALT) value group at 24 weeks after off-therapy; Gropu A2, the abnormal ALT value group at 24 weeks after off-therapy. (B) Difference in the cumulative rate of clinical suppression between B1 and group B2 (P=0.035). Group B1, patients with a history of antirival treatment. Group B2, patients without a history of antirival treatment. (C) Difference in the cumulative rate of clinical suppression among group C1, C2 and C3 (P=0.001). Group C1, HBsAg ≤500 COI, the low HBsAg value group at 48 weeks of PEG-IFN-α treatment. Group C2, HBsAg 500–6000 COI, the middle HBsAg value group at 48 weeks of PEG-IFN-α treatment. Group C3, HBsAg >6000 COI, the high HBsAg value group at 48 weeks of PEG-IFN-α treatment. HBsAg – hepatitis B surface antigen; PEG-IFN-α – pegylated interferon-alpha.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750